Leerink Partners Reiterates “Market Perform” Rating for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “market perform” rating restated by Leerink Partners in a report released on Tuesday, MarketBeat.com reports. They presently have a $1,077.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $1,175.00. Leerink Partners’ target price suggests a potential upside of 4.45% from the company’s current price.

Other research analysts also recently issued research reports about the stock. Guggenheim upped their target price on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. StockNews.com raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, September 10th. Morgan Stanley lowered their price target on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Canaccord Genuity Group reiterated a “buy” rating and issued a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Finally, JPMorgan Chase & Co. boosted their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,118.62.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $1,031.15 on Tuesday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The firm has a 50 day moving average price of $1,130.96 and a 200-day moving average price of $1,034.01. Regeneron Pharmaceuticals has a 52-week low of $769.19 and a 52-week high of $1,211.20. The firm has a market capitalization of $113.62 billion, a price-to-earnings ratio of 30.46, a PEG ratio of 3.72 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The firm had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company’s quarterly revenue was up 12.3% on a year-over-year basis. During the same period in the prior year, the firm posted $8.79 earnings per share. Equities research analysts forecast that Regeneron Pharmaceuticals will post 37.8 EPS for the current fiscal year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Marion Mccourt sold 1,137 shares of the company’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the transaction, the executive vice president now owns 12,931 shares of the company’s stock, valued at $13,540,179.41. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The disclosure for this sale can be found here. In the last ninety days, insiders sold 9,270 shares of company stock valued at $10,695,833. 7.48% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Greater Midwest Financial Group LLC boosted its position in shares of Regeneron Pharmaceuticals by 8.8% during the second quarter. Greater Midwest Financial Group LLC now owns 2,502 shares of the biopharmaceutical company’s stock worth $2,894,000 after acquiring an additional 203 shares during the last quarter. Centaurus Financial Inc. purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth $118,000. Prio Wealth Limited Partnership bought a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $210,000. Sanctuary Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $47,611,000. Finally, Kestra Investment Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth about $437,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.